Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Congenital ichthyosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Congenital ichthyosis. Displaying page 1 of 1.
    EudraCT Number: 2009-013656-77 Sponsor Protocol Number: 09-PP-02 Start Date*: 2009-10-15
    Sponsor Name:Nice University Hospital
    Full Title: Traitment of recessive nonbullous congenital ichthyosis with topic Epigallocatechin.
    Medical condition: Recessive nonbullous congenital ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021197 Ichthyoses HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-003601-10 Sponsor Protocol Number: NL69300 Start Date*: 2020-09-18
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: Treatment of Skin Severity in Ichthyosis with Hyperbaric Oxygen Therapy
    Medical condition: ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10021198 Ichthyosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003369-14 Sponsor Protocol Number: V00034 CR 309 1B Start Date*: 2006-12-12
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Efficacy and tolerance of the emollient cream V0034 CR in the symptomatic treatment of ichthyosis in children. International, multicentric, randomised, controlled, double blind study, in parallel g...
    Medical condition: Patients presenting with ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) NL (Completed) DE (Completed) LT (Completed) FR (Completed) LV (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000842-35 Sponsor Protocol Number: BT0500INT001 Start Date*: 2006-03-10
    Sponsor Name:Barrier Therapeutics, Inc.
    Full Title: A randomized, double-blind, multinational, multicenter, placebo-controlled parallel phase II/III trial to evaluate the efficacy and safety of 2 doses of oral liarozole (75 mg o.d. and 150 mg o.d.) ...
    Medical condition: Lamellar Ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10023686 Lamellar ichthyosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001796-20 Sponsor Protocol Number: RD.03.SPR.40214E Start Date*: 2013-12-17
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy, safety and pharmacokinetics of 2 concentrations and 2 dosage regimens of CD5789 in subjects with Lamellar Ichthyosis
    Medical condition: Lamellar Ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10023686 Lamellar ichthyosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003476-41 Sponsor Protocol Number: ANB019-206 Start Date*: 2021-07-17
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects with Ichthyosis
    Medical condition: Ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002205-54 Sponsor Protocol Number: P100150 Start Date*: 2013-09-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015895-87 Sponsor Protocol Number: Fuijkschot Start Date*: 2009-12-23
    Sponsor Name:UMC St Radboud
    Full Title: Application of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome
    Medical condition: Sjögren Larsson syndrome (SLS) is an autosomal recessive inherited neurometabolic disorder which is characterized by a clinical triad of congenital ichthyosis, spastic di- or tetraplegia and mental...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003272-12 Sponsor Protocol Number: 18-ICH-001 Start Date*: 2019-10-14
    Sponsor Name:Mayne Pharma LLC
    Full Title: A Phase 2 Randomized, Multi-center, Double-blind, Vehicle-controlled, 12-Week, Safety, Efficacy, and Systemic Exposure Study followed by a 12-Week Open-label Extension of Trifarotene (CD5789) Cream...
    Medical condition: Lamellar ichthyosis (LI) Autosomal Recessive Ichthyosis with Lamellar Scale
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10023686 Lamellar ichthyosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003212-22 Sponsor Protocol Number: 10MI30 Start Date*: 2013-06-03
    Sponsor Name:GOSH/ICH Joint Research & Development Office
    Full Title: Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome
    Medical condition: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003210-39 Sponsor Protocol Number: SXR001 Start Date*: 2021-11-23
    Sponsor Name:Sixera Pharma
    Full Title: A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-in-man (FTIM) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applie...
    Medical condition: Netherton-syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022284-35 Sponsor Protocol Number: R00002 CR 301 (ORF) Start Date*: 2011-03-08
    Sponsor Name:ORFAGEN
    Full Title: CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI)
    Medical condition: Lamellar Ichthyosis (LI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023686 LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) FR (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000459-35 Sponsor Protocol Number: TMB01-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Timber Pharmaceuticals, LLC
    Full Title: Protocol Title: The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - with a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (Xlinked) or ARC...
    Medical condition: Congenital ichthyosis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001948-19 Sponsor Protocol Number: IM101-603 Start Date*: 2017-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome
    Medical condition: Adults with moderately to severely Active Primary Sjögrens Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    20.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000101-37 Sponsor Protocol Number: IM128-035 Start Date*: 2017-04-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary ...
    Medical condition: subjects with moderate to severe Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    19.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001220-35 Sponsor Protocol Number: RC31-19-0045 Start Date*: 2019-10-08
    Sponsor Name:CHU de Toulouse
    Full Title: A randomized double-blinded pilot study of the efficacy and safety of dupilumab versus placebo in patients with Netherton syndrome
    Medical condition: Netherton syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000917-38 Sponsor Protocol Number: CBPR277X2101 Start Date*: 2011-09-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multip...
    Medical condition: Part 2: Atopic Dermatitis (AD) Part 3: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10003639 Atopic dermatitis LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 13:17:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA